EGFR and ovarian carcinoma: AKT1 and VEGFA were selected as most of the compounds targeted these genes, and these genes are mainly linked to ovarian cancer-related pathways, including the estrogen signaling pathway, progesterone-mediated oocyte maturation, the prolactin signaling pathway, Rap1 and ErbB signaling pathways, colorectal cancer, growth hormone action, secretion, and synthesis, and endometrial cancer.